(NASDAQ: TVTX) Travere Therapeutics's forecast annual revenue growth rate of 29.52% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 46.61%, and while it is forecast to beat the US market's average forecast revenue growth rate of 22.21%.
Travere Therapeutics's revenue in 2026 is $490,728,000.On average, 16 Wall Street analysts forecast TVTX's revenue for 2026 to be $65,522,862,627, with the lowest TVTX revenue forecast at $53,062,874,053, and the highest TVTX revenue forecast at $77,754,092,157. On average, 13 Wall Street analysts forecast TVTX's revenue for 2027 to be $83,094,877,902, with the lowest TVTX revenue forecast at $60,899,716,141, and the highest TVTX revenue forecast at $110,413,135,350.
In 2028, TVTX is forecast to generate $97,776,043,000 in revenue, with the lowest revenue forecast at $76,430,425,915 and the highest revenue forecast at $135,871,803,150.